|
Order your copy today!
|
|
Featured this month: A
list of the top 400 prescription medicines by worldwide sales. [click here]
|
 |
| Cholesterol drugs dominate: Lipitor and Zocor maintain their leading positions in the group of 200 best-selling prescription medicines |
| Brand of the year: Lipitor is setting records for sales and total prescriptions |
| Will other companies follow GlaxoSmithKline’s lead?: Consumer advocates attack GlaxoSmithKline after the company stopped supplying its prescription drugs to Canada |
 |
| Bayer at higher risk: The company is vigorously defending itself against thousands of lawsuits following the Baycol withdrawal |
| Are the states going too far?: Rebates, preferred-drug lists, and Maine’s questionable forced discount are methods being considered by states in their efforts to reduce drug costs |
| In a class of its own, for now: Amevive, the first biologic treatment approved for psoriasis, soon will be followed by other biologics with proven safety records |
| End of an error: Standardized bar coding is intended to reduce mistakes in drug administration, saving lives and increasing compliance |
| Designed to make an impact: Humira is not expected to overtake category leader Enbrel, but key advantages will lead the drug to significant market share |
 |
| Marketing Roundup: News about products on the market |
| Business Roundup: Covering business news |
| People on the Move: Promotions, comings, and goings |
| Adwise, Account Moves: Advertising agency news |
| e-marketing: Interactive media news |
| Media Beat: News from publishers and other media outlets |
| News from Rockville: Covering the FDA |
| Drug Approvals: in the United States and the world |
